Repligen Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGEN research report →
Companywww.repligen.com
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
- CEO
- Olivier Loeillot
- IPO
- 1986
- Employees
- 1,778
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $6.30B
- P/E
- 122.52
- P/S
- 8.26
- P/B
- 2.99
- EV/EBITDA
- 35.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.25%
- Op Margin
- 8.81%
- Net Margin
- 6.73%
- ROE
- 2.46%
- ROIC
- 2.18%
Growth & Income
- Revenue
- $738.26M · 16.36%
- Net Income
- $48.89M · 291.64%
- EPS
- $0.87 · 289.13%
- Op Income
- $59.58M
- FCF YoY
- -34.10%
Performance & Tape
- 52W High
- $175.77
- 52W Low
- $100.99
- 50D MA
- $118.10
- 200D MA
- $137.75
- Beta
- 1.09
- Avg Volume
- 1.09M
Get TickerSpark's AI analysis on RGEN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Madaus Martin D | other | 995 |
| May 14, 26 | Madaus Martin D | other | 2,239 |
| May 14, 26 | Konstantinov Konstantin | other | 995 |
| May 14, 26 | Konstantinov Konstantin | other | 2,239 |
| May 14, 26 | EGLINTON MANNER CARRIE | other | 995 |
| May 14, 26 | Mhatre Rohin | other | 995 |
| May 14, 26 | Mhatre Rohin | other | 2,239 |
| May 14, 26 | EGLINTON MANNER CARRIE | other | 2,239 |
| May 14, 26 | Pax Margaret | other | 995 |
| May 14, 26 | Pax Margaret | other | 2,239 |
Our RGEN Coverage
We haven't published any research on RGEN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RGEN Report →